Factors associated with guideline-concordant use of radiotherapy after mastectomy in the national comprehensive cancer network.

Dana-Farber Cancer Institute, Boston, MA, USA.
International journal of radiation oncology, biology, physics (Impact Factor: 4.18). 06/2008; 72(5):1434-40. DOI: 10.1016/j.ijrobp.2008.03.020
Source: PubMed

ABSTRACT We examined the rates and determinants of appropriate and inappropriate use of postmastectomy radiotherapy (PMRT), as defined by the National Comprehensive Cancer Network (NCCN) practice guidelines, among women with Stage I-II breast cancer (American Joint Committee on Cancer, 5th edition).
Using clinical characteristics, 1,620 consecutive patients at eight NCCN institutions who had undergone mastectomy between July 1997 and June 2002 were classified into three cohorts according to whether the guidelines (1) recommended PMRT, (2) recommended against PMRT, or (3) made no definitive PMRT recommendation. We defined the absence of PMRT in the first cohort as underuse and receipt of PMRT in the second cohort as overuse. Multivariate logistic regression analysis was applied to investigate the association of clinical and sociodemographic factors with PMRT.
Overall, 23.8% of patients received PMRT. This included 199 (83.6%) of 238 in the "recommend PMRT" cohort, 58 (5.6%) of 1,029 in the "recommend against PMRT" cohort, and 127 (38.6%) of 329 in the "consider PMRT" cohort. The only factor associated with underuse in the "recommend PMRT" cohort was nonreceipt of chemotherapy (odds ratio [OR], 0.08; p <0.0001). In addition to tumor characteristics, the factors associated with overuse in the "recommend against PMRT" cohort included age <50 years (OR, 2.28; p = 0.048), NCCN institution (OR, 1.04-8.29; p = 0.026), higher education (OR, 3.49; p = 0.001), and no reconstructive surgery (OR, 2.44; p = 0.019). The factors associated with PMRT in the "consider PMRT" cohort included NCCN institution (OR, 1.1-9.01; p <0.0001), age <50 years (OR, 2.26; p = 0.041), and tumor characteristics.
The results of our study have shown that concordance with definitive treatment guidelines was high. However, when current evidence does not support a definitive recommendation for PMRT, treatment decisions appear to be influenced, not only by patient age and clinical characteristics, but also by institution-specific patterns of care.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose Treatment decisions for patients with T1a,bN0M0 breast cancer are challenging. We studied the time trends in use of adjuvant chemotherapy and survival outcomes among these patients. Patients and Methods This was a prospective cohort study within the National Comprehensive Cancer Network Database that included 4,113 women with T1a,bN0M0 breast cancer treated between 2000 and 2009. Tumors were grouped by size (T1a, T1b), biologic subtype defined by hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status, and receipt of chemotherapy with or without trastuzumab. Results Median follow-up time was 5.5 years. Eight percent of patients with HR-positive/HER2-negative tumors were treated with chemotherapy. Fifty-two percent of those with HER2-positive or HR-negative/HER2-negative breast cancers received chemotherapy, with an increase over the last decade. Survival outcomes diverged by subtype and size, but the 5-year distant relapse-free survival (DRFS) did not exceed 10% in any subgroup. The 5-year DRFS for patients with T1a tumors untreated with chemotherapy ranged from 93% to 98% (n = 49 to 972), and for patients with T1b tumors, it ranged from 90% to 96% (n = 17 to 2,005). Patients with HR-positive/HER2-negative disease had the best DRFS estimates, and patients with HR-negative/HER2-negative tumors had the lowest. In this observational, nonrandomized cohort study, the 5-year DRFS for treated patients with T1a tumors was 100% for all subgroups (n = 12 to 33), and for patients with T1b tumors, it ranged from 94% to 96% (n = 88 to 241). Conclusion Women with T1a,b tumors have an excellent prognosis without chemotherapy. Size and tumor subtype may identify patients in whom the rate of recurrence justifies consideration of chemotherapy. These patients represent an optimal group for evaluating less toxic adjuvant regimens to maintain efficacy while minimizing short-and long-term risks.
    Journal of Clinical Oncology 06/2014; 32(20). DOI:10.1200/JCO.2013.53.1608 · 17.88 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Breast radiation therapy (RT) is a care standard following breast-conservation surgery (BCS), improving local control and survival in women. But in 2004, a Phase III trial demonstrated radiation following BCS provides no survival and limited local control benefit to women aged ≥70 with Stage I, estrogen receptor–positive cancers, who receive endocrine therapy (ET).This led to BCS+ET alone being incorporated as a Category I option in National Comprehensive Cancer Network (NCCN) Guidelines in 2004 for older women. We examined factors associated with change in radiation use in elderly patients at 13 NCCN centers. Study Design We identified women treated at NCCN centers meeting age and stage criteria, during 2000-2009. Factors considered a priori potentially associated with RT use were evaluated in univariate and multivariable models, including year of diagnosis, tumor and patient characteristics, axillary surgery, and treating institution. Date of diagnosis was classified as 2000-2004 vs 2005-2009, reflecting when guidelines changed. Results Among 1292 eligible cases, 78% received RT. In multivariable analysis, diagnosis after 2004 (P=0.0003), older age (P<0.0001), higher co-morbidity score (P=0.0006), smaller tumors (P=0.0146), and omission of axillary surgery (P<0.0001) predicted RT omission. 94% of women aged 70-74 received RT in 2000, compared with 88% in 2009. For the same times and age ≥80 RT use was 80% vs 41%. Finally, RT use was associated with treating institution (P<0.0001). Conclusions Following guideline changes for RT use in older women, NCCN centers demonstrated wide variation in implementing change. This suggests other factors are also influencing guideline uptake.
    Journal of the American College of Surgeons 10/2014; 219(4). DOI:10.1016/j.jamcollsurg.2014.05.013 · 4.45 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: As most solid tumors, surgery is often the first step of the multidisciplinary management for breast cancers. Although mastectomy and axillar lymphadenectomy still have indications, conservative treatment and sentinel node detection are commonly used. Thanks to induction chemotherapy and oncoplastic techniques, surgery is conservative in most cases, even for important tumors without overall survival prejudice. There is no consensus about resection margins status but a limit of 2 to 3 mm seems to be reasonable while oncoplastic surgery allows large resection and good cosmetic outcomes. In this overview, we present the state of the art for breast cancer surgery including conservative and radical treatments, axillar lymphadenectomy and sentinel lymph node detection, margins status, oncoplastic techniques.
    Fuel and Energy Abstracts 12/2010; 39(8). DOI:10.1016/j.jgyn.2010.10.002


1 Download
Available from